Albuquerque, NM (PRWEB) October 23, 2014
IntelliCyt Corporation, a leading provider of innovative, high-throughput, high-content cell- and bead-based screening solutions today announced the completion of the first Technology Access Program (TAP) with the first TAP awardee and partners, Dr. David Sykes and Dr. David Scadden from the Massachusetts General Hospital.
The IntelliCyt TAP Program is a collaborative outreach effort driven by applications or proposals for ambitious projects that would benefit from access to IntelliCyt’s High Throughput Flow (HTF) screening products consisting of its iQue® Screener instrumentation, ForeCyt® informatics software, and MultiCyt® reagent kits.
“We’re delighted to announce that Dr. Sykes received the first TAP award.” stated Terry Dunlay, CEO of IntelliCyt. Dr. Sykes’ use of this equipment will further his cancer discovery research in collaboration with colleagues at the Broad Institute of MIT and Harvard. Dr. Sykes stated, “Our project combines the clinical and screening expertise of scientists from the Massachusetts General Hospital and the Broad Institute with IntelliCyt’s iQue Screener.”
“IntelliCyt created our TAP Program to accelerate the development and validation of novel applications using our proprietary High Throughput Flow technology,” said Michael Sjaastad, Ph.D., Director of Business Development. “We launched the TAP Program to collaborate with pioneering scientists and commercial partners to advance the frontier of cell- and bead-based assays, and discover new therapeutic leads. This is a great example of our pursuit of those goals.”
IntelliCyt plans to continue the TAP Program, granting several awards annually, to awardees of the review process. Research institutions or companies interested in collaborating are invited to contact Michael Sjaastad or visit our website for additional details on the TAP Program application process.
About IntelliCyt Corporation
IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug screening and antibody discovery. IntelliCyt’s proprietary high throughput flow instrumentation, reagents and software solutions address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit http://www.intellicyt.com
Please send Inquiries to:
Michael Sjaastad, Ph.D.
Director of Business Development
TAP Program web page: http://www.intellicyt.com/tap.html